Aurinia Pharmaceuticals Addresses Misunderstanding
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has recently clarified its position following a retracted LinkedIn post that mentioned voclosporin by an FDA official. This response highlights the company's commitment to transparency and the efficacy of its product.
Confidence in LUPKYNIS
The pharmaceutical company stands firmly behind the favorable risk-benefit ratio of LUPKYNIS (voclosporin). This groundbreaking medication received full FDA approval in January 2021 after a comprehensive randomized clinical study called AURORA 1. The results from AURORA 1 established LUPKYNIS as a vital therapy for patients with active lupus nephritis.
AURORA 2 Study Results
In a further testament to its efficacy, LUPKYNIS was also granted approval for long-term use by the FDA following the results of the AURORA 2 study held in April 2024. This study showed consistent effectiveness of LUPKYNIS over a three-year period, demonstrating a safety profile comparable to that observed in AURORA 1, thereby reinforcing its therapeutic value.
About Aurinia Pharmaceuticals Inc.
Aurinia is dedicated to developing innovative biopharmaceuticals aimed at treating autoimmune diseases, particularly where there is a significant medical need. The approval of LUPKYNIS marked a pivotal moment for the company, as it became the first oral therapy sanctioned by the FDA for adults suffering from active lupus nephritis. This approval has opened new avenues for patients who previously had limited options.
Future Developments
In addition to LUPKYNIS, Aurinia Pharmaceuticals is actively working on the development of aritinercept (AUR200), which is designed to inhibit both the B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Aritinercept shows potential for treating a variety of autoimmune conditions, which could further strengthen Aurinia's position in the biopharmaceutical market.
Inquiries and Additional Information
For those seeking more detailed information regarding the prescribing information for LUPKYNIS, including potential side effects, you can review the resources provided. Furthermore, interested parties are encouraged to reach out with any inquiries they may have about Aurinia Pharmaceuticals and its initiatives.
Contact Aurinia
General inquiries can be directed to the company’s investor relations at ir@auriniapharma.com. This contact can provide additional insights into LUPKYNIS, ongoing studies, and future developments.
Frequently Asked Questions
What spurred Aurinia's response to the LinkedIn post?
Aurinia aimed to clarify information shared by an FDA official that could lead to misunderstandings regarding voclosporin.
What is LUPKYNIS?
LUPKYNIS (voclosporin) is an FDA-approved oral therapy for active lupus nephritis, which helps manage this autoimmune disease.
What were the results of the AURORA studies?
The AURORA studies demonstrated the efficacy and safety of LUPKYNIS, leading to its approval for use and long-term treatment.
What is aritinercept?
Aritinercept (AUR200) is a dual inhibitor currently being developed by Aurinia, aimed at treating various autoimmune diseases.
How can I obtain more information about LUPKYNIS?
Detailed prescribing information can be requested from Aurinia or found in designated medical resources.
